Statera Biopharma Signs Letter of Intent for Merger with Worksite Labs
15 mars 2023 08h00 HE
|
Statera Biopharma
FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune...
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm
14 juin 2022 07h30 HE
|
Statera Biopharma
FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical company creating next-generation immune...
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing
23 mai 2022 16h05 HE
|
Statera Biopharma
FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products
13 mai 2022 07h30 HE
|
Statera Biopharma
FORT COLLINS, Colo., May 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone
27 avr. 2022 16h10 HE
|
Statera Biopharma
FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating next-generation immune therapies that focus on...
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing
22 avr. 2022 17h26 HE
|
Statera Biopharma
FORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod
13 avr. 2022 16h05 HE
|
Statera Biopharma
FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune...
Statera Biopharma, Inc. Files Form 12b-25
31 mars 2022 16h05 HE
|
Statera Biopharma
FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...
Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022
28 mars 2022 07h30 HE
|
Statera Biopharma
Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading...
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering
24 mars 2022 17h28 HE
|
Statera Biopharma
FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation...